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Abstract
Eradication of HIV-1 from an infected individual cannot be achieved by current regimens. Viral
reservoirs established early during the infection remain unaffected by anti-retroviral therapy for a
long time and are able to replenish systemic infection upon interruption of the treatment.
Therapeutic targeting of viral latency will require a better understanding of the basic mechanisms
underlying the establishment and long-term maintenance of HIV-1 in resting memory CD4 T cells,
the most prominent reservoir of transcriptionally silent provirus. Since the molecular mechanisms
that permit long term transcriptional control of proviral gene expression in these cells are still
obscure, this review aims at summarizing the various aspects of the problem that need to be
considered. In particular, this review will focus the attention on the control of transcription
imposed by chromatin through various epigenetic mechanisms. Exploring the molecular details of
viral latency will provide new insights for eventual future therapeutics that aim at viral eradication.
Introduction
The major obstacle to HIV-1 eradication is the establish-
ment of a latent infection. In infected individuals, viral
production is a dynamic process involving continuous
rounds of infection of CD4+ T lymphocytes with rapid
turnover of both free virus and virus-producing cells that
have a half-life of 1–2 days [1,2]. The decay curves of
plasma viremia following antiretroviral treatment have
shown that after an initial fast decay, that wipes out the
majority of circulating viruses in 1–2 weeks, plasma virus
declines at a lower rate [3,4]. The half-life of this compart-
ment was estimated to be 1–4 weeks, but the nature of the
cellular reservoir responsible for the second phase in the
decay curve is still unclear. These cells could be macro-
phages, which are less sensitive to the cytopathic effect of
HIV-1 infection [5] and that once terminally differenti-
ated have a turnover rate of approximately 2 weeks. In
addition, cellular reservoirs for HIV-1 could also be CD4+
T lymphocytes not fully activated, which carry the inte-
grated provirus in a non-replicative state until the activa-
tion process is complete. Finally, dendritic cells (DCs)
may also delay the release of infectious virus, since they
are not permissive for HIV infection but can carry the virus
trapped on their surfaces [6].
After two months on HAART the plasma levels of genomic
RNA falls below the limit of detection in most previously
untreated patients. Therefore, it was initially assumed that
prolonged treatment might lead to eradication of the virus
in these patients [3]. Unfortunately, it is now clear that
long-lived reservoirs of HIV-1 can persist for years in the
presence of HAART. Although certain tissues like the male
urogenital tract or the central nervous system might pre-
serve infectious virus [7,8] the reservoir that appears to be
the major barrier to eradication is composed of latently
infected resting memory CD4+ T cells that carry an inte-
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extremely long half-life of these cells, combined with a
tight control of HIV-1 expression, make this reservoir ide-
ally suited to maintain hidden copies of the virus, which
are in turn able to trigger a novel systemic infection upon
discontinuation of therapy. Given the importance of this
reservoir, a lot of effort has been invested to characterize
these cells from infected patients. These studies will be
discussed in the following chapters, which will also
address the problem of choosing appropriate model sys-
tems to thoroughly characterize the molecular determi-
nants that allow the provirus to remain silent. Such
mechanisms are mostly related to transcriptional control
of viral expression and they depend both on the host cells
and the virus. Finally, some ideas on how to approach
viral eradication in the light of these novel findings will be
presented in the final chapter.
Source of latently infected cells
HIV-1 exploits different strategies to persist within
infected individuals. In CD4+ T lymphocytes, the replica-
tive state of the virus is dependent upon the cell cycle of
the host cell. Whereas HIV-1 entry into activated CD4+
lymphocytes leads to a productive infection [11], the virus
encounter several blocks prior to integration in resting
CD4+ lymphocytes [12]. Such post-entry blocks have
been proposed to result from a delay in completing
reverse transcription due to low nucleotide pools and to
the inability to import the pre-integration complex into
the nucleus [13-16]. Most recently the anti-retroviral
deoxycytidine deaminase APOBEC3G has been shown to
strongly protect unstimulated peripheral blood CD4+ T
cells against HIV-1 infection [17]. Furthermore, in Old
World primates, TRIM5α, a component of cytoplasmic
bodies, confers a potent block to human immunodefi-
ciency virus type 1 (HIV-1) infection that acts after virus
entry into cells, probably at the level of capsid processing
[18]. While these blocks delay the production of progeny
virus following the infection of CD4+ resting T cells,
mitogenic stimuli are able to trigger viral replication and
release of infectious virus [13,14,19-21]. Although one
would expect that activation of the cell per se would allow
more efficient reverse transcription and nuclear import,
by increasing the pools of DNA precursors and the availa-
ble ATP used for the active mobilization of the PIC, still it
is possible that specific blocks must be removed to allow
full recovery of HIV-1 infectivity. In the case of
APOBEC3G for example, activation of resting T cells
induces the shift of the active low-molecular-mass form of
APOBEC3G to an inactive high-molecular-mass complex
unable to restrict viral infection [17]. Other types of repli-
cation blocks that act after provirus integration in resting
T cells, like for example the inhibition of NF-κB activity by
Murr1 [22], will be discussed in the following chapters.
Regardless of the kind of restriction imposed by the rest-
ing T cells on viral replication, this reservoir of pre-inte-
grated latent virus is relatively labile persisting for weeks
and cannot be accounted for the long-term latency
observed during HAART.
In addition to CD4+ T lymphocytes, dendritic cells and
macrophages are considered reservoirs for HIV-1 infec-
tion, but information on the replicative state of the virus
within these cells is limited. DCs capture and internalize
extracellular virions via the DC-SIGN lectin. Captured vir-
ions can subsequently be transmitted to T cells in trans
[6]. However, DC-SIGN does not significantly protect cap-
tured virions against degradation, leading to loss of infec-
tivity within several hours [23]. In HIV-1-infected
monocyte-derived macrophages, mature viral particles
can be observed within late endosomes [24]. Virions
found within monocyte-derived macrophages persist and
retain infectivity for weeks, thus providing an additional
mechanism for viral persistence [25]. HIV-1 hidden in
DCs and macrophages certainly plays an important role
for viral spread and cell-cell transmission, but its involve-
ment in long-term viral persistence has yet to be demon-
strated.
A more stable form of latency occurs in CD4+ T cells that
carry an integrated provirus. In principle, since integration
requires T cell activation to allow efficient reverse-tran-
scription and nuclear import of the pre-integration com-
plex, post-integration latency can result only from the
return of an infected activated T cell to a quiescent state.
Evidence to this model has come from studies from Sili-
ciano and co-workers who demonstrated the existence of
resting memory CD4+ T cells carrying an integrated provi-
rus in vivo [9]. The phenotype of these resting cells carry-
ing a non-productive HIV-1 infection, derived from
peripheral blood of patients undergoing antiretroviral
therapy with low to undetectable viremia, indicates that
they derive from infected CD4+ lymphoblasts that have
reverted to a resting memory state. These cells show a spe-
cific set of surface markers (such as CD4+, CD25-, CD69-
, HLA-DR-) and are positive for the integrated provirus.
Most importantly, upon mitogen stimulation, infectious
virus can be recovered from these cells, indeed demon-
strating that they represent a true, inducible viral reservoir.
Hence, in vivo, it appears that HIV-1 gets trapped in T cells
that revert to a resting memory state. In some respect long
term HIV-1 persistence reflects directly long-term T-cell
memory. At any given time, most CD4+ T lymphocytes in
the body are in a resting G0 state. In response to antigens,
resting T cells undergo a burst of cellular proliferation and
differentiation, giving rise to effector cells. Most effector
cells die quickly, but a subset survives and reverts to a rest-
ing G0 state (contraction phase). These lymphocytes per-
sist as memory cells, with an altered pattern of genePage 2 of 9
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responses to the relevant antigen in the future. Activated
CD4+ cells are highly susceptible to HIV-1 infection and
typically die quickly as a result of the cytopathic effects
either of the virus or of the host immune response. How-
ever, some activated CD4 cells may become infected and
then survive long enough to revert back to a resting state.
Unfortunately, our current understanding of the decisive
factors that determine if a CD4+ T cells will die or become
a memory cell, as well as those that allow the self-renewal
of resting memory cells for a lifetime, is still largely
incomplete.
Models for latently infected cells
Despite the great wealth of information on the regulation
of HIV-1 transcription, the crucial molecular events that
control maintenance of the quiescent state in resting T
cells remain elusive. Part of the problem depends on the
lack of an appropriate model system. Most cell lines carry-
ing an integrated quiescent provirus have been derived
from transformed lymphoblasts that have been infected ex
vivo with HIV-1. After an initial burst of viral replication
and cell death, a population of non-productive cells carry-
ing an integrated provirus remains. Establishment of
latency in these cell lines is driven by selection of cells that
resist viral replication and has been linked to mutation in
viral genes, to certain cellular proteins and to the site of
integration [26-29]. Alternatively, T cells can be trans-
duced with an HIV-1 vector carrying Tat and a reporter
gene. This method has allowed the characterization of the
integration status irrespective of the replication of the
virus and has provided useful insights on the status of the
integrated provirus. However, the constantly activated
and proliferating nature of these cells, either infected or
transduced, does not accurately represent the quiescent
cellular environment of latently infected cells in vivo. A
convenient animal model that recapitulates HIV-1 latency
does not exist. In fact, several blocks to HIV-1 infection in
mice greatly impair the development of an animal model
to study HIV-1 infection amenable to genetic manipula-
tion. One possibility would be the use of the SCID-hu
(Thy/Liv) mouse that carries a source of human hemat-
opoietic progenitor cells and human fetal thymus to pro-
vide a microenvironment for human T cells
lymphopoiesis. Latently HIV-1 infected CD4+ T cells can
be obtained in this model, but the exact extent to which it
can be applied to natural infection is not known [30]. SIV
macaque models of AIDS are well established and have
been extremely useful in HIV-1 vaccine development and
in advancing the understanding of the pathogenesis of
AIDS. The first report exploiting the SIV-macaque model
to study viral infection in the course of antiretroviral ther-
apy showed persistence of the virus in resting CD4+ T cells
with many similarities to the human situation [31]. This
study provides initial evidence for the utility of a closely
related retroviral infection for the analysis of HIV-1 per-
sistence during antiretroviral treatment. However, the
complexity of the protocol, which also requires antiretro-
viral drugs especially designed to control SIV infection,
makes this model impractical if only for the preclinical
evaluation of novel strategies to target viral reservoirs.
Possible molecular mechanisms behind latency
Since the HIV-1 provirus is found integrated into the host
genome, regulation of viral gene expression depends on
the chromatin environment at the site of integration and
on the interaction of the viral Tat trans-activator with host
factors. Clearly, multiple mechanisms could concur in
this process.
I) Cis- and trans-acting factors involved in HIV-1 silencing
The U3 region of the HIV-1 LTR functions as the viral pro-
moter and contains consensus sequences for several tran-
scription factors, including NFAT and NF-κB, involved
also as positive regulators of cell activation in uninfected
T cells [32]. NF-κB is a key host transcription factor
required for LTR activation [33]. In resting T cells NF-κB is
sequestered in the cytoplasm bound to IκB and it is trans-
ported to the nucleus following cellular activation by TCR
engagement or stimulation by IL-2 or TNFα. NF-κB inter-
acts with two highly conserved binding sites found in the
viral LTR and promotes transcriptional activation. Murr1,
previously known for its involvement in copper regula-
tion, has been recently shown to inhibit basal and
cytokine-stimulated NF-κB [22]. Most importantly,
knockdown of Murr1 by RNAi in primary resting CD4+
lymphocytes increased HIV-1 replication. Thus, Murr-1
acts as a host restriction factor that inhibits HIV-1 replica-
tion in resting T cells.
In addition to host transcription factors, HIV-1 transcrip-
tion is boosted by the viral Tat trans-activator, a highly
unusual protein that interacts with a cis-acting RNA ele-
ment (trans-activation-responsive region; TAR) present at
the 5' end of each viral transcript [34]. Through this inter-
action, the protein activates HIV-1 transcription by pro-
moting the assembly of transcriptionally active complexes
at the LTR through multiple protein-RNA and protein-
protein interactions. Tat interacts directly with cyclin T1,
the cyclin component of CDK9, which phosphorylates the
carboxy-terminal domain of RNA polymerase II to
enhance its processivity [35,36] (reviewed in: [37]). Tat-
induced transcriptional activation of the LTR promoter is
concomitant with recruitment of the transcriptional co-
activators p300 and the highly homologue cAMP-respon-
sive transcription factor binding protein (CBP) [38-41].
These large proteins are histone acetyl-transferases capa-
ble of modulating the interaction of nucleosomes with
DNA and with other factors involved in transcription. In
fact, besides histones, Tat itself is a substrate for the enzy-Page 3 of 9
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CAF and is regulated by acetylation/deacetylation [42-47].
Furthermore, Tat is also tightly regulated by ubiquitina-
tion, further highlighting the intimate interplay between
the viral trans-activator and the host cell [48].
Tat-associated proteins could be one of the limiting fac-
tors for processive transcription in resting T cells. In this
respect, the low levels of P-TEFb kinase activity (CDK9
and Cyclin T1) that have been observed in resting T cells
are increased in response to activating stimuli [49]. Tat
itself could be the main limiting factor being subject to
tight post-translational regulation by acetylation and
ubiquitylation [42,46,48]. These data fit in a model where
limiting availability of host cell's factors and/or the viral
trans-activator concur in maintaining the virus transcrip-
tionally silent. Possible mechanisms propose premature
termination of transcription due to the absence of suffi-
cient concentrations of Tat and NF-κB [50,51] or ineffi-
cient export of RNAs for structural proteins [52]. A recent
report has also shown that fluctuations in Tat expression
alone govern stochastic gene expression of the viral LTR
[53]. However, when analyzing these studies one should
always keep in mind that they should hold true also in
resting T cells in vivo.
II) Integration-site-dependent determinants of HIV-1 
silencing
HIV-1 is found integrated into the genome of resting
memory T cells, hence the chromatin status at the site of
integration determines whether the provirus is transcrip-
tionally active, poised for activation or inactive. A recent
report [54] has analyzed the integration site of HIV-1 in
resting memory CD4+ cells derived from patient on
highly active antiretroviral treatment. Surprisingly, HIV-1
has been found in intronic regions of actively transcribed
genes. Consistently, HIV-1 sequences were included in the
unspliced RNAs of these genes. These findings, although
complicated by the high levels of dead integration events
observed (i.e. only a small fraction of resting T cells carry-
ing a silent provirus becomes productive when activated),
correlate with the observation that HIV-1 integrates in
transcriptionally active genes during productive infection
of cultured T cells [55], but are in sharp contrast with pre-
vious work showing that HIV-1 infected T cell lines
selected for a quiescent state of the provirus show prefer-
ential integration into heterochromatin [28,56]. A very
recent study helps clarifying this point showing that the
integration site of quiescent/inducible HIV-1 vectors in T
cell lines could be associated with heterochromatin, as
reported, but also with actively transcribing genes, thus
confirming the analysis in patients' cells [57]. Another
interesting observation of this work is that the inducible
state of the HIV-1 provirus could depend also upon inte-
gration in intergenic regions of gene-poor chromosomes.
However, all these three conditions: integration into het-
erochromatin, integration into highly transcribed genes
and integration into gene poor chromosomes, account for
only 40% of the inducible integration events in this sys-
tem. Notably, stochastic gene expression from the viral
LTR, a phenotype dependent on the levels of Tat, occurs
with a high frequency within 1 kb of a human endog-
enous retrovirus LTR [53]. These observations deserve fur-
ther study since they may indicate that other as yet not
identified chromatin environments at the site of provirus
integration control transcriptional silencing and reactiva-
tion. In fact, a totally different pattern might emerge, par-
ticularly considering novel concepts on the relationship
between spatial positioning of chromosomes within the
nucleus and transcription activity [58]. T cells switching
from a memory state to a lymphoblast and vice-versa
undergo a program of spatial genome reorganization of
specific genes [59-61]. HIV-1 proviruses "trapped" in a
gene that is being spatially confined in a silenced state
might become inactive and poised for activation from
external stimuli [62].
So far we have considered post-integration transcriptional
silencing as a passive consequence of chromatin status.
However, we might also consider a certain degree of bias
on the integration site driven by the association of the pre-
integration complex with certain cellular factor such as the
high mobility group (HMG) protein A1, the barrier to
autointegration (BAF), the INI1 homologous of the SNF5
component of the ATP-dependent chromatin remodeling
complex SWI/SNF and LEDGF/p75 [63-65]. BAF binds
directly to double-stranded DNA, nuclear LEM-domain
proteins, lamin A and transcriptional activators [66].
Recent observations suggest that BAF has structural roles
in nuclear assembly and chromatin organization and
might interlink chromatin structure, nuclear architecture
and gene regulation. Integrase associates also with INI
implying a role of transcription-related ATP-remodeling
complexes in determining integration. Particularly inter-
esting is the fact that INI associates with the promyelocytic
leukemia protein PML, the principal component of the
nuclear bodies [67]. These nuclear structures, whose func-
tion is still largely unknown, are dynamically associated
to the transcriptional Cyclin T1 and to co-activators such
as p300/CBP [68]. Intriguingly, IN binds also p300 and
this interaction is involved in the integration process
through acetylation of IN itself [69]. As a note of caution
it should be said that none of the above mentioned factors
that interact with the viral integrase has been shown to be
functionally expressed in resting CD4+ T cells in relation
to HIV infection. Future research will tell us more on these
interactions of HIV-1 integrase and their role in HIV-1
integration.Page 4 of 9
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RNA Interference (RNAi) was first identified as a post-
transcriptional response to exogenous double-stranded
RNA (dsRNA) introduced in C. elegans, but this mecha-
nism is conserved from plants to nematodes and mam-
mals [70-72]. RNAi is triggered by long dsRNA cleaved by
the cytoplasmic RNaselll enzyme Dicer into short, inter-
fering RNAs (siRNAs). One strand of the siRNA is incor-
porated into the effector complex of RNAi, the RNA-
induced Silencing Complex (RISC). The short RNA guides
RISC to target complementary mRNA and catalyzes an
endonucleolytic cleavage, resulting in post-transcriptional
gene silencing (PTGS) of gene expression. In mammalian
cells, siRNAs are recognized by the pathway responsible
for the activities of a class of endogenous 21–22 nt micro-
RNAs (miRNAs) (for a recent review see [73]). miRNAs
are first produced as long hairpinned precursor dsRNAs
transcribed by RNA polymerase II and are sequentially
processed by the nucleases Drosha and Dicer. The short
dsRNA produced are thought to regulate gene expression
mainly at the translational level. Many different miRIMA
genes have been predicted in humans, and they have been
implicated in the regulation of genes involved in develop-
ment and growth control [74].
RNAi-mediated pathways of transcriptional silencing
have also been shown to induce chromatin modifications
at the homologous genomic locus in plants and lower
eukaryotes (for a review: [75]). Transposable elements
and related repeats are primary targets for RNAi-mediated
pathways in the nucleus, consistent with a role for RNAi
in host defense against invasive viral sequences (for a
recent review: [76]). Silencing occurs through CG methyl-
ation by specific DNA methyltransferases that are directed
to the target by the methylation of lysine 9 of histone 3
(H3K9-Me). These findings have led to a model whereby
siRNAs directed de novo DNA methylation through the
successive action of a histone methyltransferase and DNA
methyltransferases that maintain methylation at target
DNA loci (RITS, RNA-induced transcriptional silencing)
[77].
Artificial RNAi can efficiently suppress several human
viruses, including HIV-1 [78,79]. However, this effect is
shot-term, since the virus is capable of evading the siRNA
response by random mutation of the target sequence, thus
limiting the efficacy of this antiviral approach [80]. Not
surprisingly, several viruses encode also their own miRNA
that can modulate viral replication (reviewed in: [81]).
Herpesviruses like EBV and HSHV encode miRNAs
directed against cellular and viral targets and are believed
to regulate the latent/lytic transition of these viruses
[82,83]. Short-hairpin siRNA precursors have also been
found in the HIV-1 genome. Such sequences are involved
in suppression of viral transcription unless counteracted
by the inhibition of endogenous Dicer activity targeted by
the viral Tat transactivator [84]. This mechanism is similar
to what has been observed for the primate foamy retrovi-
rus PFV-1 that is capable of subverting a cellular miRNA
block through the activity of the viral Tas protein [85].
Another HIV-1-encoded miRNA has been identified in the
nef gene and has been speculated to be a possible deter-
minant of long-term non-progression to AIDS through
inhibition of Nef function [86].
It would be intriguing to speculate also about the exist-
ence of a transcriptional pathway of HIV-1 gene silencing,
taking into account previous observations that might [87]
link CpG methylation at the HIV-1 promoter to transcrip-
tional silencing [88]. As a note of caution, however, it
should be observed that at present RNAi mediated tran-
scriptional gene silencing in human cells is highly contro-
versial, and care should be taken in extrapolating data
obtained in lower eukaryotes. Nevertheless, models such
as HIV-1 could help in disclose these archival protective
mechanisms in human cells, if they exist.
Potential therapies to eliminate latently infected 
cells
Although the implementation of HAART has improved
the survival and quality of life of HIV-infected individuals,
HIV cannot yet be eradicated from infected individuals.
Several studies have demonstrated that in individuals
receiving HAART, the frequency of HIV-infected cells is
reduced to fewer than one cell per 106 resting CD4+ T cells
[10,89,90]. However, even after years with viremia below
the limit of quantification, the frequency of these infected
cells does not decrease further. The therapeutic
approaches evaluated to date have failed to demonstrate a
significant and persistent decline of this latent viral reser-
voir [91], which appears small but stable and contains
both wild-type and drug-resistant viral species [92]. Sev-
eral studies have shown that intensive antiretroviral ther-
apy in combination with interleukin-2 or global T cell
activators fails to eradicate HIV-1 infection. Global T cell
activation may instead induce viral replication and
increase the number of susceptible uninfected target cells
beyond the threshold that can be contained by antiretro-
viral therapy [93]. Following this approach, a strategy that
selectively activates quiescent proviral genomes with lim-
ited effects on the host cell exploited the properties of the
phorbol ester Prostratin or the human cytokine inter-
leukin-7 that have been reported to reactivate latent HIV-
1 in the absence of cellular proliferation [30,94-96].
Another promising agent that has been proposed is the
histone-deacetylase inhibitor Valproic acid capable of
inducing outgrowth of HIV-1 from resting CD4+ cells of
aviremic patients without full activation of the cells from
the quiescent state [97]. Such treatments, in combination
with antiretroviral therapy, should allow outgrowth ofPage 5 of 9
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tion.
Another approach would be to target and destroy CD4+
memory cells. A study has been conducted ex vivo with an
anti-CD45RO ricin immunotoxin to decrease the number
of latently infected CD4+ T cells obtained from HIV-
infected individuals without detectable plasma viremia
[98]. Such treatment significantly reduced the frequency
of CD4+ memory cells with only a modest effect on the
memory responses of CD8+ T cells. Therefore, purging
latent cells from infected individuals on highly active
antiretroviral therapy might reduce the HIV latent reser-
voir without seriously compromising CD8+ T cell mem-
ory responses. However, this kind of approach targets
both infected and non-infected resting T cells and would
severely deplete the immunological memory of the
patient.
Conclusion
Recent advances have identified a long-lived stable reser-
voir of HIV-1 in patients on effective antiretroviral therapy
that could potentially persist for life. This reservoir con-
sists of a small pool of resting CD4+ T cells carrying an
integrated provirus that somehow control viral expression
allowing the virus to remain undetectable in plasma (Fig-
ure 1). Discontinuation of therapy and activation of cells
results in production of infectious virus leading to a novel
systemic infection. Hence, elimination of this reservoir by
novel therapeutic approaches will be required before
Schematic description of the HIV-1 life cycle highlighting the various blocks that can delay viral replication leading to prolonged hiding of the virus n the host cell during HAARTFigure 1
Schematic description of the HIV-1 life cycle highlighting the various blocks that can delay viral replication leading to prolonged 
hiding of the virus in the host cell during HAART. These include: (i) pre-integration blocks like the deoxycytidine deaminase 
APOBEC3G, the cytoplasmic body component TRIM5α (in Old World monkeys), incomplete reverse-transcription and 
defects in nuclear import; (ii) post-integration blocks such as integration into heterochromatin where transcription is 
repressed, ineffective RNAPII elongation in the absence of Tat or of key host factors, regulation of NF-kB by Murr-1; (iii) trans-
lational blocks induced by RNAi.Page 6 of 9
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lar and molecular mechanisms behind the establishment
of this remarkably stable reservoir will depend on appro-
priate in vitro model systems and in vivo animal models.
These should allow the dissection of the pathways leading
to transcriptional control of HIV-1 replication. In particu-
lar it will be crucial to correlate the activation state of host
cells with the transcription state of the provirus. Key ele-
ments to be studied are: the site of provirus integration,
which is determined by the viral integrase, and the mech-
anisms that control gene expression at these chromatin
loci, which depend mostly on the activity of the Tat trans-
activator.
It is time to seriously consider alternative therapies that
take into account the aim of eradicating infectious virus
from the patients. In order to do so an effort is needed
toward the understanding of the intimate interplay that is
established at the molecular level between the virus and
the host cell. From such studies it will be possible to
devise novel therapies that selectively target the hidden
virus.
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